GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Total Payout Yield %

CytoDyn (CytoDyn) Total Payout Yield % : -4.39 (As of Jun. 06, 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

CytoDyn's current Total Payout Yield % is -4.39%.


CytoDyn Total Payout Yield % Historical Data

The historical data trend for CytoDyn's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Total Payout Yield % Chart

CytoDyn Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Total Payout Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.79 -0.82 -0.06 -17.83 -10.73

CytoDyn Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.88 -1.97 -5.24 -1.06 -4.21

Competitive Comparison of CytoDyn's Total Payout Yield %

For the Biotechnology subindustry, CytoDyn's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where CytoDyn's Total Payout Yield % falls into.



CytoDyn Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

CytoDyn's Total Payout Yield % for the fiscal year that ended in May. 2023 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 25.786 + 0) / 240.400237
=-10.73%

CytoDyn's annualized Total Payout Yield % for the quarter that ended in Feb. 2024 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 2.68 + 0) * 4 / 254.9056875
=-4.21%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CytoDyn Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


CytoDyn Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of CytoDyn's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn (CytoDyn) Business Description

Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Executives
Tyler Blok officer: EVP of Legal Affairs 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes director
Ryan Dunlap director 310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman officer: President 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor officer: Chief Operating Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland officer: CFO, Treasurer and Secretary 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660

CytoDyn (CytoDyn) Headlines

From GuruFocus

November 2023 Letter to Shareholders

By Marketwired 11-03-2023

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

By GuruFocusNews GuruFocusNews 07-02-2022